191 related articles for article (PubMed ID: 2672019)
21. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
[TBL] [Abstract][Full Text] [Related]
22. Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder.
Zhang GK; Uke ET; Sharer WC; Borkon WD; Bernstein SM
J Urol; 1996 Jun; 155(6):1907-9. PubMed ID: 8618284
[TBL] [Abstract][Full Text] [Related]
23. [Intravesical instillation in the treatment of superficial tumors of the bladder].
Chopin DK
Prog Urol; 1998 Apr; 8(2):268-73. PubMed ID: 9615941
[TBL] [Abstract][Full Text] [Related]
24. Clinical evaluation of immunotherapy: are there differences between papillary and flat in situ bladder cancer?
Lamm DL
Cancer Surv; 1998; 31():99-108. PubMed ID: 15281319
[TBL] [Abstract][Full Text] [Related]
25. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
26. Recurrent or aggressive bladder cancer. Indications for adjuvant intravesical therapy.
Badalament RA; Ortolano V; Burgers JK
Urol Clin North Am; 1992 Aug; 19(3):485-98. PubMed ID: 1636233
[TBL] [Abstract][Full Text] [Related]
27. [Current status of the treatment of urothelial tumors].
Akaza H
Gan To Kagaku Ryoho; 1988 Feb; 15(2):205-11. PubMed ID: 3341782
[TBL] [Abstract][Full Text] [Related]
28. BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
Fisher HA
Prog Clin Biol Res; 1989; 310():275-83. PubMed ID: 2505271
[No Abstract] [Full Text] [Related]
29. The preparation, handling and use of intravesical bacillus Calmette-Guerin for the management of stage Ta, T1, carcinoma in situ and transitional cell cancer.
Brosman SA; Lamm DL
J Urol; 1990 Aug; 144(2 Pt 1):313-5. PubMed ID: 2374197
[TBL] [Abstract][Full Text] [Related]
30. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
Pham HT; Soloway MS
Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
32. Bladder contracture: review for intravesical bacillus Calmette-Guerin complication.
Hameed A; Sezian N; Thwaini A
Can J Urol; 2007 Dec; 14(6):3745-9. PubMed ID: 18163926
[TBL] [Abstract][Full Text] [Related]
33. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate.
Palou J; Xavier B; Laguna P; Montlleó M; Vicente J
Urology; 1996 Apr; 47(4):482-4. PubMed ID: 8638354
[TBL] [Abstract][Full Text] [Related]
34. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
Andius P; Holmäng S
BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
[TBL] [Abstract][Full Text] [Related]
35. Introduction and overview of intravesical therapy for superficial bladder cancer.
Soloway MS
Urology; 1988 Mar; 31(3 Suppl):5-16. PubMed ID: 3126593
[TBL] [Abstract][Full Text] [Related]
36. BCG vaccine in urinary bladder cancer.
Brosman SA
West J Med; 1991 Dec; 155(6):633. PubMed ID: 1812634
[No Abstract] [Full Text] [Related]
37. [Topical BCG therapy of in situ cancer of the urinary bladder].
Mack D; Jakse G
Urologe A; 1987 Jan; 26(1):22-5. PubMed ID: 3576860
[TBL] [Abstract][Full Text] [Related]
38. [Lower toxicity with the topical low-dose BCG therapy of superficial bladder carcinoma?].
Mack D; Frick J
Urologe A; 1992 Mar; 31(2):88-90. PubMed ID: 1561732
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of superficial tumors and carcinomas in situ of the bladder by intravesical BCG therapy].
Steg A; Leleu C; Boccon-Gibod L; Debré B
Ann Urol (Paris); 1986; 20(1):26-32. PubMed ID: 3707074
[TBL] [Abstract][Full Text] [Related]
40. Principles of intravesical chemotherapy and immunotherapy.
Sarosdy MF
Urol Clin North Am; 1992 Aug; 19(3):509-19. PubMed ID: 1636235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
